These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8772681

  • 21. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ.
    Am J Cardiol; 1995 Mar 15; 75(8):559-62. PubMed ID: 7887377
    [Abstract] [Full Text] [Related]

  • 22. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ.
    Am J Cardiol; 1997 Oct 15; 80(8):985-8. PubMed ID: 9352964
    [Abstract] [Full Text] [Related]

  • 23. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 15; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 24. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    van den Brand MJ, Simoons ML, de Boer MJ, van Miltenburg A, van der Wieken LR, de Feyter PJ.
    Eur Heart J; 1995 Nov 15; 16 Suppl L():36-42. PubMed ID: 8869017
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
    Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA.
    Am Heart J; 1999 Jul 15; 138(1 Pt 1):49-54. PubMed ID: 10385763
    [Abstract] [Full Text] [Related]

  • 28. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF.
    J Am Coll Cardiol; 1995 Dec 15; 26(7):1665-71. PubMed ID: 7594101
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE.
    Am J Cardiol; 1996 Aug 14; 78(3A):35-40. PubMed ID: 8751845
    [Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan 14; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 32. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ.
    Circulation; 2000 Jul 04; 102(1):28-34. PubMed ID: 10880411
    [Abstract] [Full Text] [Related]

  • 33. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2004 Aug 11; 292(6):696-703. PubMed ID: 15304466
    [Abstract] [Full Text] [Related]

  • 34. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1792-800. PubMed ID: 15519009
    [Abstract] [Full Text] [Related]

  • 35. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003 Nov 02; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 36. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.
    Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G.
    Circulation; 1995 Jun 15; 91(12):2882-90. PubMed ID: 7796496
    [Abstract] [Full Text] [Related]

  • 37. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors.
    Topol EJ.
    Am Heart J; 1995 Sep 15; 130(3 Pt 2):666-72. PubMed ID: 7668215
    [Abstract] [Full Text] [Related]

  • 38. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.
    Thel MC, Califf RM, Tcheng JE, Sigmon KN, Lincoff AM, Topol EJ, Ellis SG.
    Am Heart J; 1999 Feb 15; 137(2):264-73. PubMed ID: 9924160
    [Abstract] [Full Text] [Related]

  • 39. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD, Mitre CA, Barnathan E, Cavusoglu E.
    Am Heart J; 2006 Nov 15; 152(5):876-81. PubMed ID: 17070148
    [Abstract] [Full Text] [Related]

  • 40. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.